Novartis UK HCP Portal
Published on Novartis UK HCP Portal (https://www.health.novartis.co.uk)

Home > Printer-friendly > Dosing

Dosing [1]

Recommended dosing schedule and dose adjustments with KISQALI.

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.

 


Source URL: https://www.health.novartis.co.uk/medicines/oncology/kisqali/dosing

Links
[1] https://www.health.novartis.co.uk/medicines/oncology/kisqali/dosing